rulonilimab + pemetrexed + carboplatin

**rulonilimab + pemetrexed + carboplatin** is a combination therapy intended for cancer treatment. - **rulonilimab** is presumed to be a monoclonal antibody targeting PD-1/PD-L1 (functionally similar to other checkpoint inhibitors); mechanism and development specifics for rulonilimab itself are not well-documented in publicly available sources but it is presumably an immune checkpoint inhibitor. - **pemetrexed** is a folate antimetabolite chemotherapy used for non-small cell lung cancer and mesothelioma; it inhibits several key enzymes in nucleotide synthesis, leading to antiproliferative effects[1][2][3]. - **carboplatin** is a platinum-based chemotherapy that causes DNA crosslinking and apoptosis in rapidly dividing cells[1][2][3][4][5]. This combination combines an immunotherapy (checkpoint inhibition) with cytotoxic chemotherapy agents. It has been used in the context of advanced non-small cell lung cancer, as analogous combinations (e.g., pembrolizumab + pemetrexed + carboplatin) are standard of care for metastatic non-squamous NSCLC[5].